Avant Technologies forms joint venture Insulinova with Austrianova for diabetes cell therapy

AVAI BIO, INC.

AVAI and Austrianova each hold 50% of Insulinova, a JV for encapsulated insulin cell diabetes treatments.
AVAI contributes up to $1.5M in capital over 18 months for operations, plus an optional $8.5M loan for clinical testing.
Austrianova provides exclusive license to its cell encapsulation technology; Kenn Kerr CEO, Walter Günzburg Chairman.
This agreement supersedes the prior JV from Sept 19, 2025, which included Art-Islets as a party.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.